Mainstay Medical announces Half Year Financial Results

Dublin, Ireland: 22 September 2016 - Mainstay Medical International plc (Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable neurostimulation system to treat disabling Chronic Low Back Pain ("CLBP"), today announces the publication of its report for the Half Year ended 30 June 2016.

More info on Mainstay Medical's website.

Next > NGDATA Named a 2016 Cloudera Data Impact Award Winner

Previous > Leading sequencing service provider GATC Biotech adopts Bluebee for genomic analysis